Clinical Trial

A Study of YL202 in Selected Patients With Advanced Solid Tumors

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a multicenter, open-label, phase II study of YL202 in China to evaluate the efficacy, safety, and PK characteristics of YL202 in the following selected patients with advanced solid tumors.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2023-10-25; most recent amendment 2025-11-20.
Status change: Active, Not Recruiting → Recruiting 2024-11-13
Status change: Recruiting → Active, Not Recruiting 2024-06-19
Status change: Not Yet Recruiting → Recruiting 2024-01-01
Trial Details
NCT Number NCT06107686
Lead Sponsor MediLink Therapeutics (Suzhou) Co., Ltd.
Conditions NSCLC, Breast Cancer, HNSCC, Locally Advanced or Metastatic Solid Tumors
Enrollment 200 participants
Start Date 2023-12-15
Primary Completion 2026-11 (estimated)
Study Completion 2028-11 (estimated)
Updated on ClinicalTrials.gov 2025-11-26